299) lysis showed that intracranial transdural tumor extension was correlated with the hi |
300) preoperative LCN deficit had intracranial tumor extension. |
301) endent on the tumor's size and intradural tumor extension. |
302) The tumor had not changed in size subjectively |
303) athological examination revealed that the tumor had progressed to an MGCT after recu |
304) rhabdoid tumor/primitive neuroectodermal tumor had worse outcome. |
305) ere independent prognostic factors of the tumor local control (p = 0.022, 0.019, and |
306) e, and D90 were prognostic factors of the tumor local control and survival (p = 0.13 |
307) nce interval time are factors influencing tumor local control, and the recurrence in |
308) Tumor lysis syndrome, a complication of an |
309) We report tumor lysis syndrome in a patient treated |
310) irst course of trastuzumab, she developed tumor lysis syndrome. |
311) 2f1 or E2f3 led to a significant delay in tumor onset in both oncogenic models, wher |
312) n medulloblastoma incidence and a delayed tumor onset. |
313) Loss of any E2F delayed Neu-induced tumor onset. |
314) used as a carrier of anti-tumor drugs for tumor targeting by intravenous administrat |
315) omising approach to coordinating with the tumor targeting efficacy of ligand-modifie |
316) ene glycol) (PEG) grafting density on the tumor targeting efficacy of nanoparticles |
317) 131)I and (99m)TcO4 (-), and the ratio of tumor to background activity (T/B) was cal |
318) This process allows the tumor to receive its extensive nutrition d |
319) esis that hypoxia promotes cells in solid tumor to reprogram metabolic pathways in o |
320) In different tumor types due to the intrinsic immunogen |
321) The tumor types in decreasing frequency were a |
322) the use of protons to treat CNS and other tumor types is rapidly gaining popularity. |
323) imum standardized uptake value was 4.4 in Tumor 1 and 8.7 in Tumor 2. |
324) A pathological examination identified Tumor 1 as type AB thymoma and Tumor 2 as |
325) anism by which Arf causes p53-independent tumor-suppressive activity. |
326) egulator of MUC4 oncomucin that possesses tumor-suppressor activity in PDAC. |
327) inhibitor was able to effectively reduce tumor burden in vivo and block c-MET pTyr( |
328) nificantly earlier due to rapidly growing tumor burden. |
329) ere were significant associations between tumor classification and overall UPIII pat |
330) were no significant associations between tumor classification or infiltration and c |
331) A brownish-black tumor composed of large pigmented epitheli |
|